10x Genomics (NASDAQ: TXG) posts preliminary Q4 and 2025 results update

Rhea-AI Filing Summary

10x Genomics, Inc. filed a report stating that it has issued a press release with preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025. The press release, dated January 11, 2026 and attached as Exhibit 99.1, covers key financial information for that quarter and the full year. The company notes that this information is being furnished rather than filed under securities laws, which affects how it is treated for liability and incorporation into other documents.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000177078700017707872026-01-112026-01-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2026

10x Genomics, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-39035			45-5614458
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

6230 Stoneridge Mall Road

Pleasanton, California 94588

(925) 401-7300

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

___________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Class A common stock, par value $0.00001 per share

TXG

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02 Results of Operations and Financial Condition.

On January 11, 2026, 10x Genomics, Inc. issued a press release announcing preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing..

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description of Exhibits
99.1						Press Release dated January 11, 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			10x Genomics, Inc.
			By:			/s/ Randy Wu
			Name:			Randy Wu
			Title:			General Counsel and Secretary
Date: January 12, 2026

FAQ

What did 10x Genomics (TXG) disclose in this SEC filing?

10x Genomics disclosed that it issued a press release providing preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025.

Which periods do the preliminary results for 10x Genomics cover?

The preliminary, unaudited select financial results cover the fourth quarter and the full fiscal year ended December 31, 2025.

How did 10x Genomics provide these preliminary financial results?

The company provided the preliminary, unaudited select financial results in a press release dated January 11, 2026, which is attached as Exhibit 99.1.

Are the preliminary results for 10x Genomics considered filed with the SEC?

No. The company states that the information furnished under this item and in the attached press release is not deemed “filed” for purposes of Section 18 of the Exchange Act.

What exhibits are included with this 10x Genomics Form 8-K?

The exhibits include the press release dated January 11, 2026 as Exhibit 99.1 and the Cover Page Interactive Data File as Exhibit 104.

Who signed the 10x Genomics Form 8-K related to the preliminary results?

The report was signed on behalf of 10x Genomics, Inc. by Randy Wu, General Counsel and Secretary.